Latest news


Third quarter 2016 results

Posted on Nov 22, 2016

Oslo, 22 November 2016 – Please find enclosed the financial report for third quarter 2016 for PCI Biotech Holding ASA. pci-biotech-q3-2016-report Highlights fimaCHEM Completed Phase I study in bile duct cancer, with early promising results confirmed at central expert review Oral presentation of the Phase I results as late-breaking news at United European Gastro Week […]

Notice to the extraordinary general meeting to resolve a fully underwritten Rights Issue of NOK 70 million

Posted on Nov 17, 2016

Oslo, November 17, 2016 – Reference is made to PCI Biotech Holding ASA’s (“PCI Biotech” or the “Company”) stock exchange announcement earlier today that the Company convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million. The Board of Directors has resolved to call for an extraordinary general meeting […]

PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million

Posted on Nov 17, 2016

Oslo, November 17, 2016 – Reference is made to PCI Biotech Holding ASA’s (“PCI Biotech” or the “Company”) stock exchange announcement on 27 October 2016 in relation to a planned share issue of NOK 40-50 million. Having completed a thorough evaluation of its financing alternatives, and on the basis of strong investor demand and feed-back, […]